Publications by authors named "John Fastenau"

Claim this Profile
F
Frequency, duration, and cost of pulmonary exacerbations among patients with bronchiectasis.
Maitreyee Mohanty, Claudia Leiras, Haiyan Sun, Reina Rau, John Fastenau

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of non-operative management for high-grade renal injuries.
Emily M Kokush, Kunj Jain, John Fastenau, Aleksander Popovic, Meher Pandher

Int Urol Nephrol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examining adherence to American Urological Association (AUA) guidelines in men's health: Insights from the New York section AUA survey.
Hunter Hernandez, John Fastenau, Ari Bernstein, Hossein Sadeghi-Nejad

Investig Clin Urol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
Aurore Perrot, Thierry Facon, Torben Plesner, Saad Z Usmani, Shaji Kumar, John Fastenau

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A landscape review to identify what matters to patients with thrombotic cardiovascular diseases and patient-reported outcome instruments which can be used to capture the patient experience.
Alexandra I Barsdorf, John Fastenau, Shannon Lee, Xiaoyan Li, Ellen O'Brien

Qual Life Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
National Trends in PSA Cancer Screening With Parallel Investigation of Colorectal Cancer Screening: An Analysis of the CDC Behavioral Risk Factor Surveillance System From 2012 to 2022.
Anh Nguyen, John Fastenau, Juhi Mehta, Evan Kovac, Robert E Weiss

Clin Genitourin Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.
Thomas G Martin, Philippe Moreau, Saad Z Usmani, Alfred Garfall, María-Victoria Mateos, John Fastenau

Clin Lymphoma Myeloma Leuk· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag.
Stacy Davis, Teresa Edwards, Lindsey Norcross, Sheri Fehnel, Amélie Beaudet, John Fastenau

J Patient Rep Outcomes· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of Active Surveillance in Underrepresented and High-Risk Populations: Feasibility and Safety.
John Fastenau, Kunj Jain, Aleksandar Popovic, Evan Kovac

Curr Urol Rep· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study.
Adam D Cohen, Parameswaran Hari, Myo Htut, Jesus G Berdeja, Saad Z Usmani, John M Fastenau

Clin Lymphoma Myeloma Leuk· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Thomas Martin, Yi Lin, Mounzer Agha, Adam D Cohen, Myo Htut, John M Fastenau

Lancet Haematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies.
Rebecca Crawford, Katharine S Gries, Satish Valluri, John Fastenau, Ross Morrison

Cancer Rep (Hoboken)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Vaishali Sanchorawala, Giovanni Palladini, Monique C Minnema, Arnaud Jaccard, Hans C Lee, John Fastenau

Am J Hematol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
Evangelos Terpos, Meletios A Dimopoulos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, John Fastenau

Am J Hematol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the Multiple Myeloma Symptom and Impact Questionnaire: A New Patient-Reported Outcome Instrument to Assess Symptom and Impacts in Patients With Multiple Myeloma.
Katharine S Gries, John Fastenau, Caroline Seo, Barbara Potrata, Charles Iaconangelo

Value Health· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
Torben Plesner, Meletios A Dimopoulos, Albert Oriol, Jesus San-Miguel, Nizar J Bahlis, John Fastenau

Br J Haematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
Stefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, Kenshi Suzuki, Andrzej Jakubowiak, John Fastenau

BMC Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial.
Vania Hungria, Meral Beksac, Katja C Weisel, Ajay K Nooka, Tamas Masszi, John Fastenau

Br J Haematol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gaining Patient Input on Naming a Novel Patient-Reported Outcome Instrument in Chronic Weight Management.
Heather Rozjabek, John Fastenau, Samara Bennett, Lydia Min-Joo Lee

Pharmacoecon Open· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
Saad Z Usmani, Maria-Victoria Mateos, Vania Hungria, Shinsuke Iida, Nizar J Bahlis, John Fastenau

J Cancer Res Clin Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
Aurore Perrot, Thierry Facon, Torben Plesner, Saad Z Usmani, Shaji Kumar, John Fastenau

J Clin Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
Murielle Roussel, Philippe Moreau, Benjamin Hebraud, Kamel Laribi, Arnaud Jaccard, John Fastenau

Lancet Haematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptom burden and health-related quality of life impacts of smoldering multiple myeloma: the patient perspective.
Milenka Jean-Baptiste, Katharine S Gries, William R Lenderking, John Fastenau

J Patient Rep Outcomes· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychometric evaluation of the DAILY EATS questionnaire in individuals living with obesity.
John Fastenau, Heather Rozjabek, Shanshan Qin, Lori McLeod, Lauren Nelson

J Patient Rep Outcomes· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using a digital patient powered research network to identify outcomes of importance to patients with multiple myeloma.
Katharine S Gries, John Fastenau

J Patient Rep Outcomes· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis